DermTech Key Executives
This section highlights DermTech's key executives, including their titles and compensation details.
Find Contacts at DermTech
(Showing 0 of )
DermTech Earnings
This section highlights DermTech's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2023 | 2024-02-29 | $-0.54 | $-0.56 |
| Read Transcript | Q3 | 2023 | 2023-11-02 | $-0.68 | $-0.57 |
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
$0.09
Stock Price
$3.29M
Market Cap
208
Employees
La Jolla, CA
Location
Financial Statements
Access annual & quarterly financial statements for DermTech, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $15.30M | $14.52M | $11.84M | $5.88M | $3.36M |
| Cost of Revenue | $15.02M | $13.87M | $10.56M | $5.98M | $3.30M |
| Gross Profit | $276.00K | $647.00K | $1.27M | $-96.00K | $60.00K |
| Gross Profit Ratio | 1.80% | 4.46% | 10.80% | -1.63% | 1.78% |
| Research and Development Expenses | $15.24M | $24.05M | $16.26M | $5.29M | $2.50M |
| General and Administrative Expenses | $43.78M | $36.09M | $24.84M | $13.82M | $8.87M |
| Selling and Marketing Expenses | $44.99M | $58.67M | $37.58M | $16.08M | $6.30M |
| Selling General and Administrative Expenses | $88.78M | $94.76M | $62.41M | $29.90M | $15.17M |
| Other Expenses | $- | $- | $- | $- | $-355.00K |
| Operating Expenses | $104.02M | $118.81M | $78.67M | $35.19M | $17.66M |
| Cost and Expenses | $119.03M | $132.68M | $89.24M | $41.17M | $20.97M |
| Interest Income | $2.85M | $1.34M | $151.00K | $40.00K | $- |
| Interest Expense | $- | $1.34M | $- | $40.00K | $2.66M |
| Depreciation and Amortization | $5.85M | $-141.00K | $1.09M | $486.00K | $-355.00K |
| EBITDA | $-97.89M | $-118.31M | $-76.31M | $-35.29M | $-17.96M |
| EBITDA Ratio | -639.99% | -814.89% | -644.62% | -599.64% | -533.89% |
| Operating Income | $-103.74M | $-118.17M | $-77.40M | $-35.29M | $-17.61M |
| Operating Income Ratio | -678.21% | -813.92% | -653.81% | -599.64% | -523.34% |
| Total Other Income Expenses Net | $2.85M | $1.48M | $-937.00K | $-1.19M | $-2.08M |
| Income Before Tax | $-100.89M | $-116.68M | $-78.33M | $-35.25M | $-19.69M |
| Income Before Tax Ratio | -659.57% | -803.71% | -661.72% | -598.96% | -585.29% |
| Income Tax Expense | $- | $-2.96M | $-1.36M | $-526.00K | $2.21M |
| Net Income | $-100.89M | $-113.72M | $-76.98M | $-34.72M | $-21.90M |
| Net Income Ratio | -659.57% | -783.30% | -650.24% | -590.03% | -651.07% |
| EPS | $-3.09 | $-3.79 | $-2.66 | $-2.05 | $-3.13 |
| EPS Diluted | $-3.09 | $-3.79 | $-2.66 | $-2.05 | $-3.13 |
| Weighted Average Shares Outstanding | 32.64M | 30.04M | 28.88M | 16.98M | 7.01M |
| Weighted Average Shares Outstanding Diluted | 32.64M | 30.04M | 28.88M | 16.98M | 7.01M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.85M | $3.92M | $3.92M | $3.98M | $3.48M | $2.99M | $3.57M | $4.23M | $3.72M | $3.17M | $3.03M | $3.12M | $2.52M | $2.12M | $1.36M | $844.00K | $1.56M | $1.59M | $565.00K | $- |
| Cost of Revenue | $3.13M | $3.48M | $3.74M | $3.97M | $3.82M | $3.35M | $3.69M | $3.27M | $3.55M | $3.04M | $2.90M | $2.62M | $2.00M | $1.73M | $1.61M | $1.45M | $1.20M | $1.20M | $779.00K | $931.62K |
| Gross Profit | $713.00K | $440.00K | $172.00K | $8.00K | $-344.00K | $-356.00K | $-121.00K | $960.00K | $164.00K | $125.00K | $132.00K | $495.00K | $522.00K | $396.00K | $-246.00K | $-601.00K | $354.00K | $385.00K | $-214.00K | $-931.62K |
| Gross Profit Ratio | 18.50% | 11.20% | 4.40% | 0.20% | -9.90% | -11.90% | -3.40% | 22.70% | 4.40% | 3.90% | 4.40% | 15.90% | 20.70% | 18.67% | -18.06% | -71.21% | 22.74% | 24.23% | -37.88% | 0.00% |
| Research and Development Expenses | $3.27M | $3.35M | $3.60M | $3.89M | $4.41M | $5.10M | $5.70M | $6.92M | $6.34M | $5.99M | $4.43M | $3.59M | $2.25M | $1.91M | $1.62M | $864.00K | $897.00K | $650.00K | $757.00K | $- |
| General and Administrative Expenses | $10.14M | $8.42M | $8.26M | $15.22M | $11.88M | $9.83M | $8.81M | $8.88M | $8.57M | $7.16M | $6.20M | $6.30M | $5.17M | $2.84M | $2.94M | $4.53M | $3.51M | $2.42M | $3.21M | $- |
| Selling and Marketing Expenses | $7.82M | $8.42M | $8.12M | $13.03M | $15.42M | $13.60M | $14.63M | $15.00M | $15.44M | $13.33M | $9.83M | $7.91M | $6.51M | $5.10M | $4.59M | $3.43M | $2.94M | $2.43M | $1.98M | $- |
| Selling General and Administrative Expenses | $16.66M | $16.84M | $16.39M | $28.25M | $27.29M | $23.43M | $23.44M | $23.88M | $24.02M | $20.49M | $16.02M | $14.21M | $11.68M | $7.95M | $7.53M | $7.96M | $6.46M | $4.85M | $5.19M | $- |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.75M | $-131.00K | $931.62K |
| Operating Expenses | $19.92M | $20.19M | $19.98M | $32.14M | $31.70M | $28.52M | $29.14M | $30.79M | $30.36M | $26.48M | $20.45M | $17.80M | $13.94M | $9.86M | $9.15M | $8.83M | $7.36M | $5.50M | $5.95M | $931.62K |
| Cost and Expenses | $23.05M | $23.68M | $23.73M | $36.11M | $35.52M | $31.87M | $32.83M | $34.07M | $33.91M | $29.52M | $23.35M | $20.43M | $15.94M | $11.59M | $10.76M | $10.27M | $8.56M | $6.70M | $6.72M | $931.62K |
| Interest Income | $498.00K | $660.00K | $641.00K | $763.00K | $782.00K | $641.00K | $485.00K | $149.00K | $66.00K | $44.00K | $38.00K | $35.00K | $34.00K | $- | $- | $- | $- | $- | $- | $70.86K |
| Interest Expense | $- | $775.00K | $- | $- | $- | $641.00K | $485.00K | $- | $66.00K | $44.00K | $38.00K | $35.00K | $34.00K | $21.00K | $9.00K | $10.00K | $- | $- | $364.00K | $- |
| Depreciation and Amortization | $1.41M | $1.35M | $1.35M | $1.48M | $7.00K | $-15.00K | $1.10M | $963.00K | $790.00K | $733.00K | $1.16M | $208.00K | $193.00K | $180.00K | $158.00K | $88.00K | $60.00K | $31.00K | $-131.00K | $-3.22K |
| EBITDA | $-17.80M | $-18.41M | $-18.47M | $-30.66M | $-32.04M | $-28.89M | $-28.16M | $-28.87M | $-29.40M | $-26.62M | $-19.33M | $-17.27M | $-11.53M | $-9.28M | $-9.24M | $-9.34M | $-6.94M | $-5.12M | $-6.29M | $-934.84K |
| EBITDA Ratio | -462.99% | -469.06% | -471.70% | -770.33% | -921.43% | -965.06% | -788.27% | -682.05% | -790.77% | -841.11% | -637.82% | -553.67% | -456.85% | -437.72% | -678.34% | -1106.52% | -445.79% | -321.90% | -1113.27% | 0.00% |
| Operating Income | $-19.21M | $-19.75M | $-19.81M | $-32.13M | $-32.05M | $-28.88M | $-29.26M | $-29.83M | $-30.19M | $-26.36M | $-20.32M | $-17.31M | $-13.41M | $-9.46M | $-9.40M | $-9.43M | $-7.00M | $-5.12M | $-6.16M | $-931.62K |
| Operating Income Ratio | -499.56% | -503.36% | -506.00% | -807.34% | -921.63% | -964.56% | -818.95% | -704.80% | -812.02% | -832.83% | -670.59% | -554.89% | -531.42% | -446.20% | -689.94% | -1116.94% | -449.65% | -321.90% | -1090.09% | 0.00% |
| Total Other Income Expenses Net | $498.00K | $661.00K | $646.00K | $769.00K | $775.00K | $656.00K | $489.00K | $254.00K | $83.00K | $306.00K | $207.00K | $205.00K | $-1.66M | $21.00K | $9.00K | $10.00K | $104.00K | $- | $433.00K | $792.83K |
| Income Before Tax | $-20.01M | $-19.09M | $-19.16M | $-31.36M | $-31.27M | $-28.22M | $-28.77M | $-29.58M | $-30.11M | $-26.05M | $-20.11M | $-17.10M | $-15.07M | $-9.44M | $-9.39M | $-9.42M | $-7.00M | $-5.12M | $-5.73M | $-138.79K |
| Income Before Tax Ratio | -520.42% | -486.52% | -489.50% | -788.02% | -899.34% | -942.65% | -805.26% | -698.80% | -809.79% | -823.16% | -663.76% | -548.32% | -596.99% | -445.21% | -689.28% | -1115.76% | -449.65% | -321.90% | -1013.45% | 0.00% |
| Income Tax Expense | $- | $2.19M | $-646.00K | $-769.00K | $-775.00K | $-1.31M | $-978.00K | $-254.00K | $-166.00K | $-612.00K | $-414.00K | $-410.00K | $3.31M | $-42.00K | $-18.00K | $-20.00K | $- | $2.40M | $-797.00K | $-792.83K |
| Net Income | $-20.01M | $-19.09M | $-19.16M | $-31.36M | $-30.50M | $-26.91M | $-27.79M | $-29.58M | $-29.94M | $-26.05M | $-20.11M | $-17.10M | $-15.07M | $-9.44M | $-9.39M | $-9.42M | $-7.00M | $-5.12M | $-5.73M | $-138.79K |
| Net Income Ratio | -520.42% | -486.52% | -489.50% | -788.02% | -877.05% | -898.83% | -777.89% | -698.80% | -805.33% | -823.16% | -663.76% | -548.32% | -596.99% | -445.21% | -689.28% | -1115.76% | -449.65% | -321.90% | -1013.45% | 0.00% |
| EPS | $-0.58 | $-0.56 | $-0.57 | $-0.99 | $-1.00 | $-0.89 | $-0.93 | $-0.99 | $-1.00 | $-0.88 | $-0.68 | $-0.59 | $-0.55 | $-0.35 | $-0.50 | $-0.58 | $-0.53 | $-0.39 | $-0.80 | $-0.05 |
| EPS Diluted | $-0.58 | $-0.56 | $-0.57 | $-0.99 | $-1.00 | $-0.89 | $-0.92 | $-0.99 | $-1.00 | $-0.88 | $-0.68 | $-0.59 | $-0.55 | $-0.35 | $-0.50 | $-0.58 | $-0.53 | $-0.39 | $-0.80 | $-0.05 |
| Weighted Average Shares Outstanding | 34.71M | 34.33M | 33.84M | 31.79M | 30.56M | 30.25M | 29.97M | 29.96M | 29.81M | 29.73M | 29.58M | 28.98M | 27.15M | 27.15M | 18.93M | 16.15M | 13.10M | 13.10M | 7.13M | 2.63M |
| Weighted Average Shares Outstanding Diluted | 34.71M | 34.33M | 33.84M | 31.79M | 30.56M | 30.25M | 30.10M | 29.96M | 29.84M | 29.73M | 29.64M | 28.98M | 27.15M | 27.15M | 18.93M | 16.15M | 13.10M | 13.10M | 7.13M | 2.63M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $36.74M | $77.76M | $176.88M | $24.25M | $15.37M |
| Short Term Investments | $19.12M | $48.41M | $48.45M | $39.53M | $12.36M |
| Cash and Short Term Investments | $55.86M | $126.17M | $225.33M | $63.78M | $15.37M |
| Net Receivables | $2.58M | $4.17M | $3.85M | $1.48M | $680.00K |
| Inventory | $1.00M | $1.76M | $480.00K | $104.00K | $35.00K |
| Other Current Assets | $2.30M | $3.94M | $3.17M | $1.52M | $1.06M |
| Total Current Assets | $61.75M | $136.04M | $232.82M | $66.88M | $17.15M |
| Property Plant Equipment Net | $56.71M | $62.38M | $12.29M | $2.73M | $977.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $3.47M | $3.49M | $3.02M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $168.00K | $167.00K | $167.00K | $84.00K |
| Total Non-Current Assets | $60.18M | $66.04M | $15.48M | $2.90M | $1.06M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $121.93M | $202.07M | $248.31M | $69.78M | $18.21M |
| Account Payables | $1.48M | $2.42M | $2.88M | $1.57M | $1.61M |
| Short Term Debt | $3.09M | $1.75M | $1.57M | $109.00K | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $196.00K | $109.00K | $1.38M | $905.00K | $1.39M |
| Other Current Liabilities | $8.68M | $11.36M | $6.35M | $2.84M | $2.72M |
| Total Current Liabilities | $13.45M | $15.64M | $12.18M | $5.42M | $5.72M |
| Long Term Debt | $51.31M | $54.08M | $6.28M | $1.88M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $639.00K | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $-1.65M | $- |
| Other Non-Current Liabilities | $-1 | $5.00K | $146.00K | $3.30M | $- |
| Total Non-Current Liabilities | $51.31M | $54.09M | $6.43M | $865.00K | $5.03M |
| Other Liabilities | $- | $- | $- | $- | $-5.03M |
| Total Liabilities | $64.75M | $69.72M | $18.61M | $6.29M | $5.72M |
| Preferred Stock | $- | $- | $- | $69.78M | $- |
| Common Stock | $3.00K | $3.00K | $3.00K | $2.00K | $1.00K |
| Retained Earnings | $-423.94M | $-323.05M | $-206.36M | $-126.36M | $-91.11M |
| Accumulated Other Comprehensive Income Loss | $178.00K | $-774.00K | $-124.00K | $-1.00K | $- |
| Other Total Stockholders Equity | $480.93M | $456.17M | $436.18M | $118.42M | $103.60M |
| Total Stockholders Equity | $57.17M | $132.35M | $229.70M | $63.49M | $12.49M |
| Total Equity | $57.17M | $132.35M | $229.70M | $63.49M | $12.49M |
| Total Liabilities and Stockholders Equity | $121.93M | $202.07M | $248.31M | $69.78M | $18.21M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $121.93M | $202.07M | $248.31M | $69.78M | $18.21M |
| Total Investments | $22.59M | $48.41M | $48.45M | $39.53M | $12.36M |
| Total Debt | $54.39M | $55.83M | $7.86M | $335.00K | $- |
| Net Debt | $17.65M | $-21.93M | $-169.02M | $-23.91M | $-15.37M |
Balance Sheet Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $27.58M | $36.74M | $37.23M | $42.79M | $48.44M | $77.76M | $95.49M | $120.33M | $145.05M | $176.88M | $204.06M | $229.61M | $218.59M | $24.25M | $14.62M | $61.10M | $67.92M | $15.37M | $21.44M | $15.28K |
| Short Term Investments | $11.40M | $19.12M | $30.97M | $43.41M | $56.34M | $48.41M | $53.64M | $53.46M | $54.05M | $48.45M | $45.38M | $38.64M | $39.60M | $39.53M | $36.91M | $- | $- | $- | $- | $12.43M |
| Cash and Short Term Investments | $38.98M | $55.86M | $68.20M | $86.20M | $104.78M | $126.17M | $149.13M | $173.79M | $199.11M | $225.33M | $249.44M | $268.25M | $258.20M | $63.78M | $51.53M | $61.10M | $67.92M | $15.37M | $21.44M | $15.28K |
| Net Receivables | $2.50M | $2.58M | $3.60M | $3.87M | $3.69M | $4.17M | $6.10M | $5.96M | $5.00M | $3.85M | $2.82M | $2.19M | $1.85M | $1.48M | $1.01M | $722.00K | $1.18M | $680.00K | $814.00K | $- |
| Inventory | $831.00K | $1.00M | $1.20M | $1.35M | $1.57M | $1.76M | $1.39M | $1.43M | $763.00K | $480.00K | $424.00K | $497.00K | $279.00K | $104.00K | $115.00K | $83.00K | $75.00K | $35.00K | $44.00K | $- |
| Other Current Assets | $1.89M | $2.30M | $2.93M | $2.33M | $2.35M | $3.94M | $4.21M | $2.68M | $3.26M | $3.17M | $1.57M | $1.31M | $1.40M | $1.52M | $1.88M | $547.00K | $892.00K | $1.06M | $1.40M | $45.75K |
| Total Current Assets | $44.20M | $61.75M | $75.93M | $93.74M | $112.39M | $136.04M | $160.83M | $183.87M | $208.12M | $232.82M | $254.26M | $272.25M | $261.73M | $66.88M | $54.53M | $62.45M | $70.06M | $17.15M | $23.69M | $61.03K |
| Property Plant Equipment Net | $55.30M | $56.71M | $58.50M | $59.87M | $61.06M | $62.38M | $29.59M | $28.61M | $28.21M | $12.29M | $12.46M | $3.29M | $3.12M | $2.73M | $2.32M | $2.07M | $1.74M | $977.00K | $210.00K | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $3.47M | $3.47M | $3.47M | $3.47M | $3.50M | $3.49M | $3.48M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $- | $- | $168.00K | $168.00K | $167.00K | $3.64M | $3.19M | $3.19M | $3.19M | $167.00K | $167.00K | $167.00K | $167.00K | $167.00K | $167.00K | $84.00K | $84.00K | $12.43M |
| Total Non-Current Assets | $58.77M | $60.18M | $61.97M | $63.33M | $64.73M | $66.04M | $33.23M | $32.25M | $31.40M | $15.48M | $15.65M | $3.45M | $3.29M | $2.90M | $2.49M | $2.24M | $1.90M | $1.06M | $294.00K | $12.43M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $102.97M | $121.93M | $137.90M | $157.07M | $177.12M | $202.07M | $194.06M | $216.11M | $239.52M | $248.31M | $269.90M | $275.70M | $265.02M | $69.78M | $57.02M | $64.69M | $71.97M | $18.21M | $23.99M | $12.49M |
| Account Payables | $1.91M | $1.48M | $1.70M | $2.32M | $1.68M | $2.42M | $3.00M | $861.00K | $1.57M | $2.88M | $2.50M | $2.10M | $2.62M | $1.57M | $819.00K | $813.00K | $1.56M | $1.61M | $1.00M | $2.35M |
| Short Term Debt | $3.21M | $3.09M | $2.98M | $2.31M | $1.85M | $1.75M | $1.71M | $1.83M | $1.81M | $1.57M | $1.52M | $112.00K | $110.00K | $109.00K | $- | $- | $- | $- | $- | $116.15K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $203.00K | $196.00K | $236.00K | $295.00K | $242.00K | $109.00K | $417.00K | $1.31M | $1.35M | $1.38M | $1.36M | $1.37M | $1.36M | $905.00K | $1.00M | $1.02M | $1.09M | $1.39M | $1.46M | $-116.15K |
| Other Current Liabilities | $7.19M | $8.68M | $7.72M | $11.08M | $12.36M | $11.36M | $11.86M | $11.09M | $9.68M | $6.35M | $5.41M | $4.05M | $3.01M | $2.84M | $2.27M | $3.93M | $2.68M | $2.72M | $2.63M | $116.15K |
| Total Current Liabilities | $12.52M | $13.45M | $12.64M | $16.01M | $16.14M | $15.64M | $16.99M | $15.09M | $14.42M | $12.18M | $10.80M | $7.64M | $7.10M | $5.42M | $4.10M | $5.76M | $5.34M | $5.72M | $5.09M | $2.47M |
| Long Term Debt | $50.46M | $51.31M | $52.20M | $52.98M | $53.73M | $54.08M | $22.07M | $22.42M | $21.49M | $6.28M | $6.78M | $170.00K | $198.00K | $226.00K | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.00K | $133.00K | $639.00K | $679.00K | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.42M | $3.76M | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $-1 | $1.00K | $6.00K | $12.00K | $5.00K | $20.00K | $24.00K | $129.00K | $146.00K | $408.00K | $-2.84M | $-2.99M | $- | $- | $- | $- | $- | $- | $4.31M |
| Total Non-Current Liabilities | $50.46M | $51.31M | $52.20M | $52.98M | $53.74M | $54.09M | $22.09M | $22.45M | $21.62M | $6.43M | $7.18M | $749.00K | $1.10M | $865.00K | $679.00K | $1.83M | $2.65M | $3.00M | $2.46M | $4.31M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.83M | $-2.65M | $-3.00M | $-2.46M | $- |
| Total Liabilities | $62.98M | $64.75M | $64.83M | $69.00M | $69.88M | $69.72M | $39.08M | $37.53M | $36.04M | $18.61M | $17.98M | $8.39M | $8.20M | $6.29M | $4.78M | $5.76M | $5.34M | $5.72M | $5.09M | $6.78M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $57.02M | $64.69M | $71.97M | $- | $23.99M | $- |
| Common Stock | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $2.00K | $2.00K | $2.00K | $1.00K | $1.00K | $1.00K | $4.05M |
| Retained Earnings | $-443.94M | $-423.94M | $-404.84M | $-385.68M | $-354.32M | $-323.05M | $-294.82M | $-266.05M | $-236.47M | $-206.36M | $-180.31M | $-160.20M | $-143.10M | $-126.36M | $-116.92M | $-107.53M | $-98.11M | $-91.11M | $-86.00M | $1.66M |
| Accumulated Other Comprehensive Income Loss | $184.00K | $178.00K | $127.00K | $-101.00K | $-289.00K | $-774.00K | $-1.09M | $-865.00K | $-694.00K | $-124.00K | $-8.00K | $2.00K | $8.00K | $-1.00K | $-57.02M | $-64.69M | $-71.97M | $- | $-23.99M | $- |
| Other Total Stockholders Equity | $483.75M | $480.93M | $477.78M | $473.86M | $461.85M | $456.17M | $450.90M | $445.49M | $440.64M | $436.18M | $432.24M | $427.50M | $399.91M | $188.20M | $169.16M | $166.46M | $164.74M | $103.60M | $104.89M | $- |
| Total Stockholders Equity | $39.99M | $57.17M | $73.06M | $88.08M | $107.24M | $132.35M | $154.99M | $178.58M | $203.48M | $229.70M | $251.92M | $267.31M | $256.83M | $63.49M | $52.25M | $58.93M | $66.63M | $12.49M | $18.89M | $5.71M |
| Total Equity | $39.99M | $57.17M | $73.06M | $88.08M | $107.24M | $132.35M | $154.99M | $178.58M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $102.97M | $121.93M | $137.90M | $157.07M | $177.12M | $202.07M | $194.06M | $216.11M | $239.52M | $248.31M | $269.90M | $275.70M | $265.02M | $69.78M | $57.02M | $64.69M | $71.97M | $18.21M | $23.99M | $12.49M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $102.97M | $121.93M | $137.90M | $157.07M | $177.12M | $202.07M | $194.06M | $216.11M | $239.52M | $248.31M | $269.90M | $275.70M | $265.02M | $69.78M | $57.02M | $64.69M | $71.97M | $18.21M | $23.99M | $12.49M |
| Total Investments | $14.87M | $22.59M | $30.97M | $43.41M | $56.34M | $48.41M | $53.64M | $53.46M | $54.05M | $48.45M | $45.38M | $38.64M | $39.60M | $39.53M | $36.91M | $- | $- | $- | $- | $12.43M |
| Total Debt | $53.67M | $54.39M | $55.17M | $55.29M | $55.58M | $55.83M | $23.78M | $24.25M | $23.30M | $7.86M | $8.30M | $282.00K | $308.00K | $335.00K | $- | $- | $- | $- | $- | $116.15K |
| Net Debt | $26.09M | $17.65M | $17.94M | $12.50M | $7.14M | $-21.93M | $-71.71M | $-96.08M | $-121.75M | $-169.02M | $-195.76M | $-229.33M | $-218.29M | $-23.91M | $-14.62M | $-61.10M | $-67.92M | $-15.37M | $-21.44M | $100.87K |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-100.89M | $-116.68M | $-78.33M | $-35.25M | $-19.69M |
| Depreciation and Amortization | $5.85M | $4.46M | $2.30M | $486.00K | $89.00K |
| Deferred Income Tax | $-29.76M | $- | $- | $13.00K | $-573.00K |
| Stock Based Compensation | $18.57M | $18.93M | $13.28M | $4.97M | $1.30M |
| Change in Working Capital | $11.00K | $-2.56M | $-1.20M | $1.12M | $664.00K |
| Accounts Receivables | $1.59M | $-325.00K | $-2.37M | $-800.00K | $-100.00K |
| Inventory | $753.00K | $-1.28M | $-376.00K | $-69.00K | $5.00K |
| Accounts Payables | $-1.85M | $1.88M | $4.33M | $827.00K | $1.34M |
| Other Working Capital | $-482.00K | $-2.84M | $-2.79M | $1.16M | $-578.00K |
| Other Non Cash Items | $29.25M | $585.00K | $1.85M | $-21.00K | $414.00K |
| Net Cash Provided by Operating Activities | $-76.98M | $-95.26M | $-62.11M | $-28.68M | $-17.79M |
| Investments in Property Plant and Equipment | $-902.00K | $-3.31M | $-2.72M | $-1.83M | $-210.00K |
| Acquisitions Net | $960.00K | $-650.00K | $-123.00K | $39.51M | $- |
| Purchases of Investments | $-34.39M | $-31.50M | $-48.09M | $-41.71M | $- |
| Sales Maturities of Investments | $65.16M | $30.48M | $38.30M | $2.20M | $- |
| Other Investing Activities | $-960.00K | $650.00K | $123.00K | $-39.51M | $- |
| Net Cash Used for Investing Activities | $29.86M | $-4.32M | $-12.51M | $-41.34M | $-210.00K |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $6.19M | $22.00K | $230.45M | $42.99M | $19.80M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $6.08M | $917.00K | $230.28M | $78.90M | $28.62M |
| Net Cash Used Provided by Financing Activities | $6.08M | $917.00K | $230.28M | $78.90M | $28.62M |
| Effect of Forex Changes on Cash | $20.00K | $- | $- | $- | $- |
| Net Change in Cash | $-41.02M | $-98.66M | $155.66M | $8.87M | $10.62M |
| Cash at End of Period | $36.74M | $81.25M | $179.91M | $24.25M | $15.37M |
| Cash at Beginning of Period | $77.76M | $179.91M | $24.25M | $15.37M | $4.75M |
| Operating Cash Flow | $-76.98M | $-95.26M | $-62.11M | $-28.68M | $-17.79M |
| Capital Expenditure | $-902.00K | $-3.31M | $-2.72M | $-1.83M | $-210.00K |
| Free Cash Flow | $-77.88M | $-98.56M | $-64.83M | $-30.52M | $-18.00M |
Cash Flow Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | June 30, 2019 | March 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-20.01M | $-19.09M | $-19.16M | $-31.36M | $-31.27M | $-28.22M | $-28.77M | $-29.58M | $-30.11M | $-26.05M | $-20.11M | $-17.10M | $-15.07M | $-9.44M | $-9.39M | $-9.42M | $-7.00M | $-5.12M | $-138.79K | $-4.92K |
| Depreciation and Amortization | $1.41M | $1.35M | $1.35M | $1.48M | $1.67M | $1.49M | $1.10M | $1.07M | $807.00K | $733.00K | $1.16M | $208.00K | $193.00K | $180.00K | $158.00K | $88.00K | $60.00K | $31.00K | $- | $- |
| Deferred Income Tax | $- | $-4.80M | $- | $7.36M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $2.70M | $3.15M | $3.16M | $7.51M | $4.74M | $5.27M | $4.94M | $4.84M | $3.89M | $3.83M | $3.74M | $3.54M | $2.17M | $1.45M | $1.37M | $1.12M | $1.02M | $104.00K | $- | $- |
| Change in Working Capital | $-1.11M | $2.07M | $-4.24M | $-672.00K | $2.86M | $208.00K | $-2.17M | $-481.00K | $-112.00K | $-1.22M | $-642.00K | $515.00K | $148.00K | $1.07M | $-300.00K | $1.82M | $-1.48M | $469.00K | $905.91K | $799.38K |
| Accounts Receivables | $87.00K | $1.02M | $260.00K | $-175.00K | $482.00K | $1.93M | $-139.00K | $-967.00K | $-1.15M | $-1.03M | $-634.00K | $-331.00K | $-374.00K | $-473.00K | $-285.00K | $453.00K | $-495.00K | $135.00K | $- | $- |
| Inventory | $173.00K | $192.00K | $156.00K | $222.00K | $183.00K | $-366.00K | $41.00K | $-669.00K | $-283.00K | $-56.00K | $73.00K | $-218.00K | $-175.00K | $11.00K | $-32.00K | $-8.00K | $-40.00K | $9.00K | $- | $- |
| Accounts Payables | $362.00K | $-174.00K | $-3.05M | $-479.00K | $1.17M | $1.94M | $1.01M | $-214.00K | $161.00K | $2.48M | $259.00K | $1.16M | $443.00K | $1.04M | $494.00K | $2.00K | $-714.00K | $7.00K | $900.41K | $- |
| Other Working Capital | $-1.73M | $1.03M | $-1.61M | $-240.00K | $1.03M | $-3.29M | $-3.08M | $1.18M | $1.16M | $-2.61M | $-340.00K | $-92.00K | $254.00K | $492.00K | $-477.00K | $1.37M | $-229.00K | $318.00K | $5.51K | $799.38K |
| Other Non Cash Items | $4.78M | $4.62M | $-146.00K | $-7.51M | $-28.00K | $33.00K | $106.00K | $-464.00K | $696.00K | $26.00K | $-43.00K | $30.00K | $1.84M | $-8.00K | $- | $- | $- | $-1.57M | $-792.82K | $-808.95K |
| Net Cash Provided by Operating Activities | $-17.12M | $-12.71M | $-19.04M | $-23.20M | $-22.03M | $-21.23M | $-24.80M | $-24.41M | $-24.82M | $-22.68M | $-15.90M | $-12.81M | $-10.72M | $-6.75M | $-8.16M | $-6.38M | $-7.40M | $-6.08M | $-25.70K | $-14.49K |
| Investments in Property Plant and Equipment | $- | $163.00K | $-49.00K | $-259.00K | $-757.00K | $-1.93M | $-12.00K | $-714.00K | $-646.00K | $-1.06M | $-720.00K | $-932.00K | $-12.00K | $-257.00K | $-376.00K | $-1.03M | $-175.00K | $-157.00K | $- | $- |
| Acquisitions Net | $- | $-12.08M | $-12.81M | $-13.32M | $485.00K | $-650.00K | $454.00K | $- | $- | $-123.00K | $- | $- | $9.00K | $-2.20M | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $-20.00K | $-8.80M | $-9.09M | $-16.48M | $-5.08M | $-6.25M | $-6.51M | $-13.66M | $-22.94M | $-20.25M | $-3.70M | $-1.20M | $-4.80M | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $7.83M | $12.10M | $21.61M | $22.40M | $9.04M | $10.55M | $5.79M | $7.37M | $6.77M | $19.48M | $13.38M | $4.45M | $1.00M | $2.20M | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $77.00K | $12.08M | $12.81M | $13.32M | $-485.00K | $650.00K | $-454.00K | $855.00K | $- | $123.00K | $- | $- | $-9.00K | $2.20M | $-36.91M | $- | $- | $- | $- | $136.91M |
| Net Cash Used for Investing Activities | $7.83M | $12.24M | $12.76M | $13.06M | $-8.19M | $3.54M | $-466.00K | $141.00K | $-7.53M | $-4.52M | $-7.60M | $-178.00K | $-215.00K | $-2.86M | $-37.28M | $-1.03M | $-175.00K | $-157.00K | $- | $136.91M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $126.00K | $- | $483.00K | $4.50M | $270.00K | $22.00K | $477.00K | $- | $- | $- | $- | $- | $- | $19.10M | $- | $-2.00K | $23.89M | $-1.00K | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $122.00K | $-24.00K | $726.00K | $4.46M | $916.00K | $-33.00K | $433.00K | $-10.00K | $527.00K | $25.00K | $971.00K | $24.00M | $205.28M | $19.23M | $-1.04M | $589.00K | $60.12M | $174.00K | $10.50K | $-136.91M |
| Net Cash Used Provided by Financing Activities | $122.00K | $-24.00K | $726.00K | $4.46M | $916.00K | $-33.00K | $433.00K | $-10.00K | $527.00K | $25.00K | $971.00K | $24.00M | $205.28M | $19.23M | $-1.04M | $589.00K | $60.12M | $174.00K | $10.50K | $-136.91M |
| Effect of Forex Changes on Cash | $- | $-1.00K | $- | $13.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-9.16M | $-489.00K | $-5.56M | $-5.68M | $-29.31M | $-17.72M | $-24.83M | $-24.27M | $-31.83M | $-27.18M | $-22.52M | $11.01M | $194.35M | $9.62M | $-46.48M | $-6.82M | $52.55M | $-6.06M | $-15.21K | $-14.49K |
| Cash at End of Period | $27.58M | $36.74M | $40.70M | $46.26M | $51.94M | $81.25M | $98.97M | $123.80M | $148.08M | $179.91M | $207.09M | $229.61M | $218.59M | $24.25M | $14.62M | $61.10M | $67.92M | $15.37M | $15.28K | $30.49K |
| Cash at Beginning of Period | $36.74M | $37.23M | $46.26M | $51.94M | $81.25M | $98.97M | $123.80M | $148.08M | $179.91M | $207.09M | $229.61M | $218.59M | $24.25M | $14.62M | $61.10M | $67.92M | $15.37M | $21.44M | $30.49K | $44.98K |
| Operating Cash Flow | $-17.12M | $-12.71M | $-19.04M | $-23.20M | $-22.03M | $-21.23M | $-24.80M | $-24.41M | $-24.82M | $-22.68M | $-15.90M | $-12.81M | $-10.72M | $-6.75M | $-8.16M | $-6.38M | $-7.40M | $-6.08M | $-25.70K | $-14.49K |
| Capital Expenditure | $- | $163.00K | $-49.00K | $-259.00K | $-757.00K | $-1.93M | $-12.00K | $-714.00K | $-646.00K | $-1.06M | $-720.00K | $-932.00K | $-12.00K | $-257.00K | $-376.00K | $-1.03M | $-175.00K | $-157.00K | $- | $- |
| Free Cash Flow | $-17.12M | $-12.54M | $-19.09M | $-23.46M | $-22.79M | $-23.16M | $-24.81M | $-25.12M | $-25.47M | $-23.74M | $-16.62M | $-13.74M | $-10.73M | $-7.00M | $-8.53M | $-7.41M | $-7.57M | $-6.24M | $-25.70K | $-14.49K |
DermTech Dividends
Explore DermTech's dividend history, including dividend yield, payout ratio, and historical payments.
DermTech News
Read the latest news about DermTech, including recent articles, headlines, and updates.
Why Is DermTech (DMTK) Stock Down 26% Today?
DermTech (NASDAQ: DMTK ) stock is falling on Monday as investors prepare for the molecular diagnostic company's shares to be delisted later this week. DermTech received a notice from the Listing Qualifications Department of the Nasdaq Exchange notifying it of its delisting.
DermTech Files for Voluntary Chapter 11 Protection
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DM.
DermTech Reports First-Quarter 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results. First-Quarter 2024 Financial Results Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. Total revenue wa.
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, lice.
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California. The first research abstract, “Non-invasive gene expression analyses to rule out melanoma in patients with Fitzpatrick skin types IV-VI” will be prese.
DermTech Reports Fourth-Quarter 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results. “We reported sustained improvement in many of our key performance indicators during the second half of last year and will continue emphasizing average selling price (ASP) and revenue growth in 2024,” said Bret Christensen, CEO, DermTech. “We've aligned our commercial ef.
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results. In advance of the call on February 29, 2024, DermTech will issue its fourth-quarter 2023 earnings press release. For participants interested in aski.
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced additional restructuring actions to prioritize revenue growth, streamline operations and further reduce overall operating expenses. The Company has continued to rigorously evaluate its growth opportunities and operations, while dedicating substantially all of its resources to growing reimbursed DermTech Melanom.
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from a study evaluating the foundational gene expression assay component of the DermTech Melanoma Test (DMT) across all skin types in the real-world clinical setting. The peer-reviewed study entitled, “Non-invasive gene expression analysis rules out melanoma with high negative predictive.
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that it will discontinue the optional TERT promoter mutation add-on assay for its DermTech Melanoma Test (DMT) effective March 1, 2024. Multiple studies, including the Company's recently completed Trust 2 Study, demonstrated the DMT's negative predictive value (NPV) to be 99% or higher. A high NPV for a rule-ou.
DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DermTech, Inc. (NASDAQ: DMTK) on behalf of long-term stockholders following a class action complaint that was filed against DermTech on October 15, 2023 with a Class Period from May 3, 2022 to November 3, 2022. Our investigation concerns whether the board of directors of DermTech have breached their fiduciary duties to the company. According.
DMTK DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action – DMTK
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DermTech, Inc. (NASDAQ: DMTK) between May 3, 2022 and November 3, 2022, both dates inclusive (the “Class Period”), of the important December 15, 2023 lead plaintiff deadline. SO WHAT: If you purchased DermTech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO D.
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in DermTech, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 15, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DermTech, Inc. ("DermTech" or "the Company") (NASDAQ:DMTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 8, 2021 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before December 15, 2023.
DMTK DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action - DMTK
NEW YORK , Dec. 14, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DermTech, Inc. (NASDAQ: DMTK) between May 3, 2022 and November 3, 2022, both dates inclusive (the "Class Period"), of the important December 15, 2023 lead plaintiff deadline. SO WHAT: If you purchased DermTech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the grant to 15 new employees of restricted stock units representing the contingent right to receive up to an aggregate of 56,230 shares of the Company's common stock under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan. The restricted stock units were approved by DermTec.
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DermTech, Inc. (DMTK)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) securities between March 8, 2021 and November 3, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On August 8, 2022, after the market closed, DermTech announce.
DERMTECH INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In DermTech To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $25,000 investing in DermTech stock or options between March 8, 2021 and November 3, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/DMTK.
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in DermTech, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DermTech, Inc. ("DermTech" or "the Company") (NASDAQ:DMTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 8, 2021 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before December 15, 2023.
SHAREHOLDER ALERT: Levi & Korsinsky Notifies DermTech, Inc.(DMTK) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Dec. 12, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DermTech, Inc. ("DermTech" or the "Company") (NASDAQ: DMTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DermTech investors who were adversely affected by alleged securities fraud between March 8, 2021 and November 3, 2022.
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in DermTech, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DermTech, Inc. ("DermTech" or "the Company") (NASDAQ:DMTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 8, 2021 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before December 15, 2023.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in DermTech, Inc. of Class Action Lawsuit And Upcoming Deadline - DMTK
NEW YORK , Dec. 10, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against DermTech, Inc. ("DermTech" or the "Company") (NASDAQ: DMTK) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 23-cv-02221 is on behalf of persons and entities that purchased or otherwise acquired DermTech securities between March 8, 2021 and November 3, 2022, inclusive (the "Class Period").
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in DermTech, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DermTech, Inc. ("DermTech" or "the Company") (NASDAQ:DMTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 8, 2021 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before December 15, 2023.
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action - DMTK
NEW YORK , Dec. 7, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DermTech, Inc. (NASDAQ: DMTK) between May 3, 2022 and November 3, 2022, both dates inclusive (the "Class Period"), of the important December 15, 2023 lead plaintiff deadline. SO WHAT: If you purchased DermTech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in DermTech, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DermTech, Inc. ("DermTech" or "the Company") (NASDAQ:DMTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2022 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before December 15, 2023.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for DMTK.